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Several polysulfonate compounds have been shown to have the potential to inhibit the replication of herpesviruses by
blocking binding and penetration of the host cell. We analyzed the actions of the polysulfonate compound suramin on the
replication of herpes simplex virus type 1 (HSV-1) and compared them with the actions of heparin. We used the expression
of a reporter gene (b-galactosidase) recombined into the latency-associated transcript region of the 17syn1 strain of HSV-1
to quickly evaluate productive cycle activity and have shown that it can be directly correlated with virus replication under the
conditions used. We find that suramin, like heparin, blocks the binding of HSV-1 to the cell membrane. Also, suramin efficiently
blocks the cell-to-cell spread of the virus; this effect has not been previously reported. Our control experiments demonstrate
that heparin also has some effect on intercellular spread of HSV-1 but to a significantly lesser degree than does suramin.
We suggest that suramin and related polysulfonate compounds have potential for developing of antiherpes treatments.
© 1999 Academic Press
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The interaction between the neurotropic herpes sim-
lex virus (HSV) and its natural host, humans, is well
ontrolled with little sequelae after primary infection and
he establishment of latent infections in sensory and
utonomic neurons innervating the mucosal tissues
here primary infection takes place (Wagner and Bloom,
997). Despite its generally unremarkable course, infec-
ions with HSV type 1 can lead to life-threatening en-
ephalitis and ocular infections that result in corneal
nflammation and scarification (Corey and Spear, 1986a,
986b; Nesburn, 1998). Thus the rare complications of
SV infections can have a significant impact on the
uality of life of those with it. For example, in developed
ountries, many corneal transplants are performed as a
onsequence of scarification caused by HSV-1 infection,
nd in developing countries, this scarification is a major
ause of blindness.
For these reasons, the development of clinically rele-
ant anti-HSV agents is of great importance. Most anti-
SV agents target the virus-encoded enzymes involved
n viral genome replication, such as the viral DNA poly-
erase (Spector et al., 1998). These drugs include fos-
arnet (phosphonoformic acid) and several nucleoside
nalogs such as acyclovir (ACV) and related compounds.
CV is the most clinically used anti-HSV because it
educes severity, duration, and recurrence with very little
1 To whom reprint requests should be addressed. Fax: (949) 824-
a370. E-mail: ewagner@uci.edu.
141oxicity; however, ACV does not completely eliminate all
f the symptoms, and virulent ACV resistant strains have
een generated as a result of poor patient compliance
ith the treatment (Coen, 1996, 1995, 1994). Therefore, it
s of interest to develop new anti-HSV agents that sub-
titute for or complement ACV.
Another attractive target for anti-HSV agents is the
omplex process of virus entry into its host cell. This
rocess involves several of the virus envelope glycopro-
eins, as well as cellular membrane proteins (WuDunn
nd Spear, 1989). The initial attachment of the virus to the
ell membrane involves specific binding of viral glyco-
roteins B and C (gB–UL27; gC–UL44) to cellular heparan
ulfate proteoglycans (Herold et al., 1994, 1991; Laquerre
t al., 1998). This attachment is followed by the fusion of
he viral envelope with the cell membrane that is medi-
ted by gB, gD (US6), and the gH–gL (UL22 and 1-)
omplex (Cai et al., 1988; Desai et al., 1988; Hutchinson
t al., 1992; Roop et al., 1993). Several membrane recep-
ors that mediate this fusion has been reported (Mont-
omery et al., 1996; Geraghty et al., 1998). The cell-to-cell
assage of the virus seems to occur via a process
ifferent from virus entry and involves gE and gI (US7;
S8; Dingwell and Johnson, 1998) and gB (Laquerre et al.,
998).
Polysulfonate compounds such as heparin have been
hown to block the attachment of HSV-1 by preventing
he competitive binding of viral glycoproteins to heparan
ulfate proteoglycans. The drug suramin is a symmetri-
al polysulfonate napthylamine derivative of urea, a fre-
uently used antitrypanosome agent, which also has
ntitumor and antiviral actions, and it is able to inhibit
0042-6822/99 $30.00
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142 AGUILAR, RICE, AND WAGNEReveral enzymatic and receptor activities (Voogd et al.,
993; Rotlla´n et al., 1998). Although the anti-HSV proper-
ies of suramin have been known for several years (Alar-
o´n et al., 1984), its mechanism of action has not been
eported. We analyzed the mechanism of the anti-HSV
ction of suramin and compared it with that of heparin.
or this, we used a procedure to quickly evaluate pro-
uctive cycle activity by the use of an HSV-1 recombinant
n which the reporter bacterial b-galactosidase gene
nder the control of the early UTPase (UL50) promoter
as been engineered to replace the latency-associated
ranscript, which has no role in productive infection
Wagner and Bloom, 1997).
Our results show that suramin, as well as heparin, can
nhibit HSV-1 infection of Vero cells by blocking virion
ttachment to the cells. In addition, suramin prevents the
ell-to-cell spread of the virus, a novel action described
or a polysulfonate compound. Heparin also has this
roperty but is not as efficient.
RESULTS
eporter b-galactosidase expression at 24 h p.i. is
roportional to PFU in low multiplicity infections.
Reporter genes are expressed with the kinetics and
evels of wild-type genes when controlled by the same
romoters in recombinant viruses (Wagner et al., 1998).
urthermore, we have previously shown that the recom-
inant virus (dUTPase/LAT) in which the b-galactosidase
ene controlled by the early dUTPase promoter replaces
he promoter and 59 regions of the LAT gene replicates
ith efficiency equivalent to wild-type virus in cultured
ells (Huang et al., 1993; Huang and Wagner, 1964).
ecause this recombinant virus has a full complement of
he wild-type productive cycle genes, we chose it to
tudy certain aspects of virus–cell interactions in culture.
In this context, we observed that when cultures of Vero
ells were infected with small amounts of virus, the
eporter gene activity correlated well with the amount of
irus added. This observation suggested the possibility
f using b-galactosidase activity to rapidly measure pro-
uctive infection in cultures infected with low m.o.i. To
est whether this correlation was quantitative, both the
umber of plaques formed and the total activity of b-ga-
actosidase were evaluated in parallel infections (Fig.
A). Replicate cultures of 105 Vero cells in 24 wells plates
ere infected with amounts of HSV varying between 50
nd 1000 PFU using dilutions of the same virus stock.
our replicate infections were carried out for each input
.o.i., and b-galactosidase activity was determined in
wo of the infected cultures, whereas the other two were
arvested and total PFU produced was measured by
laque assay. We found an excellent correlation between
he activity of b-galactosidase and the number of
laques formed (correlation coefficient r2 5 0.92; Bailey, t995). At m.o.i. of .1, this relationship was not obtained
Fig. 1B).
There could be several reasons for the loss of reci-
rocity at m.o.i. of .1. These include a relative reduction
n the efficiency of transcription and translation machin-
ry in multiply infected cells and an early onset of cyto-
athic effects due to the higher m.o.i. Despite such
omplications, which we did not further investigate, the
bservations indicate that reporter gene expression at
n m.o.i. of ,1 PFU/cell provides a rapid and accurate
lternative to plaque assays. Accordingly, we used such
eporter gene activity assays to investigate the effect of
uramin treatment on virus replication in cultured cells.
uramin present at time of infection markedly
educes infection efficiency
In a preliminary experiment, we found by carrying out
nfections at an m.o.i. of 0.1 PFU/cell that the percentage
f control activity obtained with 20, 50, and 100 mM
uramin were 67, 16, and 4, respectively. We subse-
uently used 100 mM suramin to determine how this
nhibition of virus multiplication depends on the initial
.o.i. (Fig. 1B). In the experiment shown, cultures of 105
ero cells in 24-well plates were infected with amounts
f virus ranging from 102 to 106 PFU/culture. Suramin was
resent both during virus adsorption and in the overlay
edium.
As established above, in the control (untreated) cul-
ures, the b-galactosidase activity at 22 h p.i. was directly
roportional to the infecting virus between 102 and 104
FU corresponding to m.o.i. of 0.001–0.1. There was a
roportional decrease in activity concomitant with ob-
ervable cell lysis at higher initial m.o.i. (not shown). The
ddition of 100 mM suramin reduced reporter enzyme
ctivity levels over the range of m.o.i. values. At the
igher levels of input virus, a reduction in the extent of
ell lysis was also observed (data not shown).
We confirmed that the drug had no effect on the mea-
urement of b-galactosidase activity. Thus when we in-
luded suramin in the reaction buffers for b-galactosi-
ase activity assay, we found no alteration in the rate of
roduct formation (data not shown). In subsequent ex-
eriments, we carried out infections of 24-well plates
ith 500 PFU of virus. These conditions result in a strong
olor reaction, when using an aliquot of one eighth of the
ample.
uramin can block the binding of the virus
o the cells
The polysulfonated nature of suramin suggested that a
ajor point of inhibition would be at the point of virus
dsorption and penetration. To begin analyzing the
echanism of action of suramin on viral productive cycle
ctivity, we examined the effect of its addition at various
imes during a single round of virus replication in cul-
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143SURAMIN AND HSV ENTRYured cells (Fig. 2). Accordingly, we treated the cells with
00 mM suramin either for 2 h before adsorption, during
he (1 h) adsorption phase while the cells were exposed
o the virus suspension in PBS glucose (see Materials
nd Methods), or immediately after the replacement of
he virus suspension by the overlay medium. Combina-
ions of these treatments were also assessed. Suramin
educed the virus-induced reporter gene expression
hen present both during and after adsorption. In con-
rast, when cells were pretreated with suramin before the
ddition of the virus, there was no reduction in reporter
ene expression. The cytotoxic effect of suramin on
eLa cells takes place at much higher concentrations
FIG. 1. (A) Correlation between virus yield and reporter gene activity in
f 105 Vero cells in 24-well plates were infected with recombinant
-galactosidase gene controlled by the early dUTPase promoter (Huang
h) Data for an m.o.i. of 0.001. (F) Data for an m.o.i. of 0.002. ({) Data
arvested, and virus yield and b-galactosidase activity were measured
nfected at different m.o.i. Cultured Vero cells were infected with the in
M) was present during the adsorption phase and in the overlay media
etermined. Data are the average of three duplicate determinations anAlarco´n et al., 1984). In addition, the pretreatment of Vero 5ells with 100 mM for 24 h before infection did not cause
nhibition in virus yield.
To further analyze the mechanism suramin action, we
etermined the dose-response of inhibition under the
ifferent conditions of drug treatment (Fig. 3). When the
rug was present during adsorption, the shape of the
ose-response curve was typically sigmoid with the re-
ponse occurring between 1 and 100 mM (IC50 5 20 6 10
M). This is the expected shape for a first-order effect
i.e., one in which the major inhibitory response is at a
ingle point in the virus life cycle). In contrast, when
resent after adsorption, suramin demonstrated a bipha-
ic dose-response: at concentrations ranging from 20 to
es infected with recombinant HSV-1 (dUTPase/LAT). Duplicate cultures
n which the 59 portion of the LAT gene was substituted with the
993, 1994). (}) Data for an initial infection with 50 pfu (m.o.i. 5 0.0005).
.o.i. of 0.005. (n) Data for an m.o.i. of 0.01. At 24 h p.i., cultures were
ffect of suramin on reporter gene expression in cultures of Vero cells
number of pfu of the dUTPase/LAT recombinant virus. Suramin (100
h p.i., the level of productive activity (reported by b-galactosidase) was
shown 6S.D. Control (solid), suramin (open).cultur
HSV i
et al., 1
for an m
. (B) E
dicated
. At 220 mM, the drug caused an increase in reporter gene
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144 AGUILAR, RICE, AND WAGNERxpression, but there was inhibition of virus-induced
eporter gene expression at higher concentrations (IC50
70 6 9 mM). We found that the degree of the observed
timulation varied with the age of the cells in culture. It
ay reflect potentiation by the drug of virus entry, but we
id not investigate the effect in detail at this time. When
uramin is present both during and after adhesion, the
hape of the curve is similar to that obtained when
uramin is present only during adsorption, with the same
C50 value (20 6 11 mM).
The inhibition of virus-induced reporter gene expres-
ion when suramin is present during the adsorption
eriod suggests that the binding of the virus to the cells,
ts fusion with the membrane and entry into cells, or both
rocesses are sensitive to its action. To decide between
hese possibilities, we carried out the adhesion of the
irus at 0°C (Fig. 3). Under these conditions, virus can
ind to its receptors on the surface of the cell, but fusion
f the viral and cell membranes and virus entry do not
ccur (Huang and Wagner, 1964; Immergluck et al., 1998).
t 0°C, the reduction in virus replication resulting from
uramin (IC50 5 17 6 11 mM) treatment was very similar
o that observed when the adhesion is carried out at
7°C (IC50 5 20 6 10 mM).
FIG. 2. Effect of suramin on reporter gene expression when present
ere infected with 500 pfu of the dUTPase/LAT recombinant. Treatmen
hase (before); suramin present during the adsorption phase (during); a
f these treatments were also assessed. Reporter b-galactosidase a
eterminations and are shown 6S.D.To ensure there was no penetration of the virus when ahe adhesion was carried out at 0°C, we treated the cells
ith citric buffer at pH 3.0 immediately after removal of
he viral suspension. This treatment inactivates the virus
ound to the cell surface but not viruses fused with the
ells (Huang and Wagner, 1964). The level of productive
ctivity in infected cultures submitted to this treatment
as about 1% of control values. These results show that
uramin can inhibit the binding of the virus to the cells
hen present during the adhesion.
uramin has no effect on HSV DNA replication and
irion assembly
Our results show that suramin blocks virus adsorption
o Vero cells. We next investigated whether this drug has
ny effect on a later stage of HSV replication after ad-
orption. To address this question, we added suramin at
ifferent times after adsorption (Fig. 4). We found that
hen suramin was added at times up 10 h postadsorp-
ion, there was an almost complete inhibition of the
roductive infection activity.
We further defined the point in the virus infection cycle
t which the drug acts by adding suramin immediately
fter adsorption and harvesting cells at various times
rent phases of the infection. Cultured Vero cells (105 in 24-well plates)
as follows: suramin (100 mM) present for 2.5 h before the adsorption
amin present for 21 h after the adsorption period (after). Combinations
as determined at 22 h p.i. Data are the average of three duplicateat diffe
ts were
nd sur
ctivity wfter this instead of at 22 h p.i. Here, the titer of infectious
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145SURAMIN AND HSV ENTRYirus present in the cell extracts was measured by
laque assay (Fig. 5). A 10-fold net increase in virus titer
ompared with cultures isolated immediately after infec-
ion was observed by 10 h p.i., but there was no differ-
nce between suramin-treated and control cultures. Still,
n cultures in which suramin was present until 24 h p.i.,
irus yield was reduced by nearly 2 logs compared with
ntreated control cultures. This result strongly suggests
hat the only point in the virus replication cycle affected
y suramin is at the point of virus infection or spread, not
t a stage influencing genome replication or virus as-
embly.
We confirmed the lack of any effect of suramin addition
n viral DNA replication by direct measurement. We
easured viral DNA using the quantitative PCR methods
FIG. 3. Effect of different concentrations of suramin on the inhibiti
f 105 Vero cells in 24-well plates were infected with 500 pfu of the dU
as present during the adsorption period. (B) The indicated amount
his. (C) The indicated amounts of drug were present for 21 h, after ad
dsorption at 0°C for 2 h. The activity of the b-galactosidase repor
uplicate assays 6S.D.escribed previously (Devi-Rao et al., 1994, 1997). This aeasurement is based on determining the ratio of HSV
o cellular DNA at various times p.i. The amplified signal
or HSV DNA was produced using a virus-specific primer
et (VP5 in this case), and a primer set specific for the
ellular actin gene was used to measure levels of cellu-
ar DNA. As shown in Fig. 6, the relative ratio of viral to
ellular DNA was essentially the same in control and
uramin-treated cultures of infected cells isolated 6 and
h p.i.
uramin inhibits cell-to-cell movement of HSV
Because the assembly of infectious virus was not
mpaired at early times p.i. by the addition of suramin
fter virus adsorption and entry (Fig. 5), it seemed prob-
SV replication as measured by reporter gene expression. Cultures
/LAT HSV-1 recombinant. (A) The indicated concentration of suramin
g was present during both the adsorption period and for 21 h after
n. (D) The indicated concentrations of suramin were present during
e was measured 22 h p.i. Data are the average of three to sevenon of H
TPase
of dru
sorptio
ter genble that the drug blocked either virus release from
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146 AGUILAR, RICE, AND WAGNERnfected cells or the intercellular spread of the virus. To
ecide between these two possibilities, we determined
he amount of infectious virus released into the medium
f untreated cultures of HSV infected cells and compared
his value with that obtained in cultures of infected cells
reated with control cultures at 24 h p.i. The relative
mount of infectious virus found in the culture media was
6 1% of that found in the cells (Table 1). This indicates
hat few infectious virions are released by this time p.i.
FIG. 4. Sensitivity of infected Vero cells to suramin added at various
imes p.i. Vero cells (105 in 24-well plates) were infected with 500 pfu of
he dUTPase/LAT recombinant. After the adsorption phase, 100 mM
uramin was added at the indicated times. Productive infection was
easured by reporter b-galactosidase activity determined at 22 h p.i.
ata are the average 6S.D. of three or four separate determinations in
uplicate.
FIG. 5. Production of HSV from infected cultures treated with suram
nfected with 500 pfu of the dUTPase/LAT recombinant. Suramin (10
arvested at the indicated times after the addition of virus to the cultu
ars are control, and filled bars are suramin treated. Each bar are the
, C), and 8 (24, S) separate determinations.he proportion of infectious virus found in the media of
uramin-treated infections was actually greater than that
n the control cultures (17 6 9%); from this we conclude
hat suramin treatment did not reduce the proportion of
nfectious virus released into the medium.
These observations are consistent with suramin hav-
ng an effect on the intracellular spread of the virus
hrough cell contact. To test this possibility, we examined
he spread of virus between cells using histochemical
ethods to visualize b-galactosidase-expressing cells
Fig. 7). In the presence of 200 mM suramin, no plaques
ere seen, but many single stained cells were observed
n the presence of suramin. The number of such b-ga-
actosidase-expressing cells was roughly equivalent to
he number of plaques in control cultures (319 6 30
laques/well and 289 6 21 cells/well).
As a control experiment, we examined the effect of the
ddition of neutralizing pooled human immunoglobulin
IgG) on virus plaque formation. In the absence of
uramin, 0.05% IgG has no effect on plaque formation,
onfirming the limited release of virus from infected cells
nder the conditions of infection used (328 6 27
laques/well in the presence of IgG and 319 6 30
laques/well in the absence). When 100 mM suramin
as present, however, plaque formation was eliminated,
ut the number of single b-galactosidase-expressing
ells measuring the number of initially infected cells was
nchanged (271 6 26 cells/well in the presence and
89 6 21 cells/well in the absence).
r virus adsorption. Cultures of 105 Vero cells in 24-well plates were
was added immediately after the 1-h adsorption period. Cells were
virus yield was measured in drug-treated and control cultures. Open
e 6S.D. of 8 (1 h), 9 (6 h, C), 8 (6 h, S), 6 (10 h, C), 6 (10 h, S), 11 (24in afte
0 mM)
re, and
averag
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147SURAMIN AND HSV ENTRYhe action of suramin is similar to the effect of
eparin on HSV adsorption and spread
Heparin is a sulfonated polysaccharide that has long
een known to interfere with the attachment of HSV to
ells (Hochberg and Becker, 1968; Jackson et al., 1991).
ecause these are properties shared with suramin, we
ecided to examine the effects of heparin on HSV repli-
ation under the same conditions that we used to study
uramin as a general control for our methods and con-
lusions. Like suramin, heparin blocked virus replication
hen present during the virus adsorption period or when
dded just after this (Fig. 8). Also like the situation with
uramin, the dose-response relation between HSV rep-
ication and heparin was biphasic when the drug was
dded after virus adsorption. There was a stimulation of
irus-induced reporter gene expression in the presence
f low concentrations of the drug, but an inhibition at
igher concentrations. A minor difference between the
ose-responses of heparin and suramin on HSV infec-
ion was observed. The inhibitory concentration of hep-
rin when present during adsorption was 20-fold less
han when present after adsorption (IC50 5 0.2 6 0.1
nit/ml versus 4 6 2 unit/ml). This difference is only 3- to
-fold with suramin (IC50 5 20 6 10 mM versus 70 6 9
M for the two treatments).
DISCUSSION
The results shown here indicate that the antiherpetic
ction of suramin results from its abilities to block HSV-1
ttachment to the cells and to prevent intercellular
pread of the virus. The fact that heparin and suramin
ave similar properties strongly suggests that suramin
xerts its action by altering the interactions of HSV-1 with
eparan sulfate on the cell membrane.
FIG. 6. Quantitative PCR analysis of HSV DNA replication in suramin-
reated cells. Total DNA isolated from cultures of 105 Vero cells infected
ith 500 pfu of the dUTPase/LAT recombinant was PCR amplified
nder quantitative conditions as described in Materials and Methods
nd more fully by Devi-Rao et al. (1994, 1997). Aliquots (20%) of the
mplified products were fractionated in 6% polyacrylamide gels in
ris–borate–EDTA and quantified as described. S, suramin infections;
, control infections.To carry out these studies, we described a quick andonvenient procedure to evaluate productive infection.
or this, we used the recombinant virus HSV-1 (dUTPase/
AT) in which a reporter cassette with bacterial b-galac-
osidase controlled by the HSV dUTPase promoter was
ecombined into both LAT sites in the long repeat re-
ions of the HSV-1 genome activity (Huang et al., 1993,
994). Thus using a simple colorimetric procedure, it is
ossible to have a measure of productive cycle activity in
–3 h compared with the 2–3 days required for plaque
ssays.
A major action of suramin is to prevent virus attach-
ent to cells. This conclusion is drawn from the results
btained when the attachment is carried out in the cold
o prevent penetration of the virus. Under these condi-
ions, the inhibition curve obtained is practically coinci-
ent with the curve obtained when the adsorption is
arried out at 37°C (Fig. 3). The first step in HSV adsorp-
ion to susceptible cells generally is the interaction be-
ween viral glycoproteins and heparan sulfate on the cell
urface (Shieh et al., 1992). We suggest that the action of
uramin on virus attachment is via interference with this
inding. It is notable that suramin contains many sulfate
esidues in its structure that may prevent the binding of
iral glycoproteins to heparan sulfate in the same man-
er as heparin. Also, suramin is a potent inhibitor of
eparanase in melanomas (Nakajima et al., 1991), and
uramin can displace heparin binding to HIV-1 Tat pro-
ein (Rusnati et al., 1998).
Suramin can also interfere with the intercellular
pread of HSV after its initial replication in an infected
ell. When suramin is added as late as 10 h p.i., there is
n extensive blockade of reporter gene expression as-
ayed 12 h later (Fig. 4). This indicates that secondary
nfection of neighboring cells is not occurring. This inter-
retation of our data is confirmed by the fact that histo-
hemical analysis of infected centers shows that the
ddition of suramin or heparin after virus adsorption has
o effect on the number of cells initially infected; rather,
t inhibits the formation of multiply infected centers of
nfection (Fig. 7).
None of our data indicate that suramin has any effect
n the macromolecular processes involved in virus ge-
TABLE 1
Effect of Suramin on the Release of HSV from Infected Vero Cells
reatment Cell-Associated Virusa Virus in Mediuma Ratio
Control 491,555 6 127,147 9831 6 4915 0.02 6 0.01
Suramin 17,983 6 9285 3057 6 1618 0.17 6 0.09
Note. Vero cells (105 in 24-well plates) were infected with 500 pfu of
he dUTPase/LAT recombinant. Suramin (100 mM) was added immedi-
tely after the adsorption phase. At 24 h p.i., the medium was separated
rom the cells, the cells were scrapped, and virus recovery was deter-
ined by standard plaque assay.
a The pfu recovered (average of six separate determinations 6 SD).
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148 AGUILAR, RICE, AND WAGNERome replication and virion assembly and maturation.
hus, the amount of infectious virus recoverable from
ells treated with suramin for the first 10 h after virus
FIG. 7. Histochemistry of suramin- and heparin-treated cells. Cult
UTPase/LAT recombinant. Suramin (200 mM) or heparin (400 U/ml) wa
ith 5% glutaraldehyde, and b-galactosidase was visualized using X-gdsorption is the same as control cultures, and viral DNA cields are equivalent when cells are treated for 6 to 8 h
fter virus adsorption (Figs. 5 and 6).
The inhibition on cell-to-cell spread of HSV by suramin
Vero cells (105 in 1 cm2 wells) were infected with 300 pfu of the
d immediately after the adsorption phase. At 22 h p.i., cells were fixed
ing as described in Materials and Methods.ures of
s addeould also be mediated by altering virus interaction with
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149SURAMIN AND HSV ENTRYeparan sulfate. It has been recently reported that the
inding of HSV-1 gB to heparin is reduced when a se-
uence containing a series of lysine residues is removed
rom gB by mutation (Laquerre et al., 1998). An HSV-1
ecombinant containing this mutated protein generates
maller plaques than the wild-type virus. This indicates
hat the cell-to-cell spread of HSV-1 is mediated by gB
hat binds to heparan sulfate via these lysine residues. In
ddition, HSV-1-induced cell fusion appears to be medi-
ted by heparan sulfate because it can only occur in
hinese hamster ovary cells deficient for heparan sulfate
hen heparin is present (Shieh and Spear, 1994).
We argue that if suramin prevents cell-to-cell spread
hrough binding to heparan sulfate proteoglycan, heparin
as a similar action. As shown in Fig. 7, heparin (like
uramin) blocks virus amplification when added after
irus attachment. Thus its presence results in the forma-
ion of HSV plaques smaller than those in control infec-
ions. To the best of our knowledge, the reduction in the
ell-to-cell spread of HSV-1 by heparin has not been
FIG. 8. Effect of various concentrations of heparin on reporter gene
xpression in infected cultures. Cultures of 105 Vero cells in 24-well
lates were infected with 500 pfu of the dUTPase/LAT recombinant.
he indicated concentration of heparin was present (A) during the
dsorption phase or (B) for 21 h after virus adhesion. Productive
nfection was measured by reporter b-galactosidase activity at 22 h p.i.
ata are the average of three separate duplicate assays 6S.D.eported previously. Takemoto and Fabish (1964) ob- Eerved that in infections at an m.o.i. of 1023 HSV/cell,
eparin reduced viral growth when added after adsorp-
ion, but the authors did not examine the plaque size, and
hey speculated that heparin was blocking the binding of
ewly released virus to uninfected cells. In contrast, it
as reported that heparin added after virus penetration
as no effect on HSV replication (Nahmias and Kibrick,
964; Hochberg and Becker, 1968). These earlier studies
robably missed the effect of heparin that we are report-
ng for two reasons. First, low heparin concentrations
ere used, and we have shown here that the IC50 value
or heparin after viral adhesion is 10- to 20-fold higher
han that when heparin is present during adsorption.
econd, a high m.o.i. was used, and we have found that
he effects reported here are only reproducible at a low
.o.i. Thus when we used an m.o.i. of 2, both heparin and
uramin cause no reduction of productive infection (the
umber of PFU recovered were 29 6 7 3 106 in controls,
1 6 1 3 106 in suramin-treated wells and 30 6 12 3 106
n heparin-treated wells from a 24-well plate, n 5 4).
Our data show that suramin is more effective that
eparin in preventing the lateral diffusion of HSV-1. Thus
uramin completely inhibits plaque formation that is
erely reduced in the presence of heparin. It is possible
hat suramin has other actions besides blocking virus
inding to heparan sulfate. For instance, it may interact
ith herpes virus entry mediator (HVEM, renamed HveA),
hich is also involved in the cell-to-cell spread of the
irus (Roller and Rauch, 1998). In this light, it is of interest
hat suramin can block tumor necrosis factor-a receptor
Alzani et al., 1993), which is structurally related to HVEM
Montgomery et al., 1996).
Despite this correlation, it is known that cell-to-cell
pread of HSV-1 can take place in murine L cells deficient
n heparan sulfate (Gruenheid et al., 1993). In this case,
ntercellular spread may depend on the chondroitin sulfate
resent on the surface of these cells (Banfield et al., 1995).
t would be of some interest to determine whether suramin
nd heparin have a similar effect on such cells.
We conclude that suramin very effectively blocks the
ateral diffusion of HSV-1 after low multiplicity infection,
ossibly by affecting the virus interactions with heparan
ulfate on the cell surface. Thus it may serve as a very
seful tool for investigating virus infections in single cells,
n increasingly important approach toward the study of
iral latency and reactivation. The action of the compound
ay also be of interest for the development of new antiher-
etic treatments. In addition, the methology presented
ould be of interest for studying the action of antivirals at
ow m.o.i.
MATERIALS AND METHODS
ell culture and virus
Vero cells and rabbit skin fibroblast were cultured in
agle’s minimum essential medium containing 5% bo-
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150 AGUILAR, RICE, AND WAGNERine serum and supplemented with 100 U/ml penicillin
nd 100 mg/ml streptomycin; the cultures were main-
ained at 37°C under 5% CO2. Rabbit skin cell fibroblasts
ere used to grow the virus and Vero cells for plaque
ssay and to analyze the action of suramin.
Vero cells cultures 80–90% confluent in 24-well
lates (;105 cells/well) were infected with recombi-
ant HSV-1 (dUTPase/LAT) (Huang et al., 1993, 1994)
ontaining the bacterial b-galactosidase gene under
he control of the UTPase promoter placed in the locus
f the LAT gene virus. Typically, infections were car-
ied out at an m.o.i. of 0.005 (500 PFU/culture). For this
nfection, the medium was removed, and the wells
ere rinsed with saline. The cells were incubated with
he virus suspended in 0.5 ml of glucose-PBS (10%
lucose, 1% FCS in PBS containing 100 U/ml penicillin
nd 100 mg/ml streptomycin) for 1 h at 37°C with slow
ocking. This incubation will be referred to as “adsorp-
ion.” After this incubation, the virus suspensions were
emoved, the wells were rinsed with saline, and 0.5 ml
f overlay medium was added; incubation continued at
7°C under 5% CO2 for the required period.
Infections for virus plaque assay were carried out by
he same procedure but using 6-well plates. Adhesions
ere carried out with virus suspensions in 1 ml of glu-
ose-PBS; then 1 ml of overlay containing 0.05% neutral-
zing antibodies medium was added.
emiquantitative PCR analysis of viral DNA levels
Vero cells (105 in 24-well plates) were infected with
00 PFU of HSV-1 (dUTPase/LAT). Cells were har-
ested, and DNA was extracted at appropriate times
.i. Extraction was performed by resuspending the
ells in 0.8 ml of DNA extraction buffer (10 mM Tris, pH
.5, 25 mM EDTA, 100 mM NaCl, 2% SDS). After this, 50
l of proteinase K solution (15 mg/ml) was added, and
he cells were digested overnight at 48°C. The DNA
olution was extracted three times with phenol–chlo-
oform and once again with chloroform. The DNA was
recipitated with ethanol and dissolved in 200 ml of
ater.
Then 20 ml of the DNA solution (10%) was used for
ach PCR. PCR amplification was carried out by methods
escribed previously (Devi-Rao et al., 1994, 1997). The
ollowing primer sets (sense strand/antisense strand)
ere used: VP5 (149-bp product), 59-TGAACCCCAGC-
CCAGAAACC-39/59-CGAGTAAACCATGTTAAGGACC-39;
abbit actin (110 bp), 59-AAGATCTGGCACCACACCTT-39/
9-CGAACATGATCTGGGTCCATC-39. Reactions were
arried out in an M. J. Research thermal cycler as fol-
ows: denaturation at 94°C for 30 s, annealing at 55°C for
0 s, and extension at 72°C for 60 s. The final cycle was
erminated with a 10-min extension step. Products were
ade radioactive for autoradiography and image quan-ification by adding 0.2 mCi of [a-32P]dCTP. Twenty-per- Cent aliquots of the amplified products were fractionated
n 6% polyacrylamide gels in Tris–borate–EDTA. The
CR signals were visualized by scanning exposed auto-
adiographs with use of a Deskcan II scanner (Hewlett-
ackard). Signals from several different exposures were
uantified by densitometry using JP laboratory software
Signal Analysis Corp.) to ensure reciprocity.
easurement of b-galactosidase activity in infected
ell cultures
After 22–24 h p.i., the medium was removed, and the
ells were resuspended in 1.5 ml of 10% sucrose PBS.
he cells were sedimented by centrifugation at 2000g for
0 min at room temperature. The supernatant was re-
oved, and the cell pellet was resuspended in 200 ml of
0% sucrose-PBS and permeabilized by three cycles of
reeze–thawing. Aliquots of 25 ml of these suspensions
ere mixed with 0.5 ml of incubation buffer (1.2 mM
gCl2, 60 mM KHPO4, pH 7.8), and chlorophenol red-b-
-galactopyranoside (Boehringer Mannheim) was added
o 5 mM final concentration. The reaction was allowed to
roceed for 30 min at room temperature and stopped by
dding 200 ml of 20% lactose. Product was measured by
etermining absorbency at 550 nm.
-Galactosidase histochemistry
Infected Vero cells cultures were fixed with 5% glutar-
ldehyde for 10 min at room temperature and rinsed
hree times with saline. The staining solution (1 mg/ml
-gal, 5 mM ferrocyanide, 5 mM ferricyanide, 1 mM
gSO4 in PBS) was added. The reaction was allowed to
roceed at 37°C until the blue color developed (usually
0–60 min). The staining solution was then removed, and
he cells were washed with PBS and stored in this buffer
t 4°C.
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